Aeglea BioTherapeutics, Inc./$SYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Primary listing
Employees
102
Headquarters
Website
SYRE Metrics
BasicAdvanced
$3.2B
-
-$1.98
3.16
-
Price and volume
Market cap
$3.2B
Beta
3.16
52-week high
$45.76
52-week low
$10.91
Average daily volume
711K
Financial strength
Current ratio
13.253
Quick ratio
12.943
Profitability
Effective tax rate (TTM)
0.01%
Management effectiveness
Return on assets (TTM)
-19.80%
Return on equity (TTM)
-25.17%
Valuation
Price to book
5.74
Price to tangible book (TTM)
5.74
Price to free cash flow (TTM)
-16.214
Free cash flow yield (TTM)
-6.17%
Free cash flow per share (TTM)
-2.533
Growth
Earnings per share change (TTM)
-37.88%
3-year earnings per share growth (CAGR)
-57.01%
10-year earnings per share growth (CAGR)
-42.27%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $3.2B as of March 10, 2026.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of March 10, 2026.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of March 10, 2026.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 3.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.